Navigation Links
Biota makes major antiviral discovery

Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection. Biota has filed worldwide patents and selected a lead candidate with a series of backups for further preclinical development prior to human clinical trials.

RSV infection is an important medical need and already a billion-dollar market, with growing visibility among pharmaceutical companies. The currently marketed drug is an injectable antibody with 2004 sales of approximately US$1 billion ($1.3 billion). However, its use is limited to prevention of infection, not treatment, and it is currently only approved for use in the highest risk group of patients: premature infants. If successful, the Biota RSV drug is expected to have significant advantages and could expand the market to include treatment as well as prevention and to other 'at risk' patient segments, such as children, the elderly and people with underlying respiratory conditions.

Latest results in two animal models also demonstrate that Biota's new RSV antivirals are effective when administered orally. This should allow the product to be developed in a convenient oral formulation, such as a tablet or suspension.

"The discovery of a novel, orally available RSV antiviral is a major achievement," said Dr Simon Tucker, Vice President of Research for Biota. "Others, including several large pharmaceutical companies, have discovered and disclosed RSV antivirals, but many are inhaled products. Orally effective RSV compounds appear to be a rarity. This is an exciting achievement for Biota and Australian research."

The current compounds are the result of research conducted by the Biota team over several years. Since 2003, this research has been supported by a $2.7m R&D Start grant from the Australian government. The RSV development follows on the heels of the company's recent decision to advance its common cold (human rh inovirus, HRV) drug candidate into clinical development following a similarly successful in-house research program.


'"/>

Source:Biota


Related biology news :

1. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
2. Grass makes environmentally friendly biofuel
3. Shampoo detergent added to paint makes surfaces self-sterilizing
4. Green diesel: New process makes liquid transportation fuel from plants
5. Discovery that bacterium is phosphate gourmet key clue to what makes it most social of bacteria
6. Technique makes it easier to see mouse embryo in all its glory
7. In the minds eye: How the brain makes a whole out of parts
8. African parasite makes component of fat differently from all other organisms
9. Coffee makes us more likely to say yes
10. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
11. Embryonic patterning makes the feathers fly
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology: